An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain
An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain
The purpose of this study is to assess the safety of the long-term use of pregabalin at doses
 up to 600 mg/day in patients with central neuropathic pain (post spinal cord injury pain,
 post stroke pain, and multiple sclerosis pain).
Inclusion Criteria:

 Inclusion criteria for subjects to be shifted from Study A0081107

 -  Subjects who completed the 18-week study period in Study A0081107 conducted for
 chronic neuropathic pain after spinal cord injury;

 -  Subjects who completed assessments of all efficacy endpoints until the end of the
 treatment phase of the preceding Study A0081107 (V7);

 Inclusion criteria for subjects to be new participants in this study

 -  Subjects with central neuropathic pain after stroke or multiple sclerosis;

 -  At least 6 months have passed after the onset of central neuropathic pain;

 -  Pain VAS at least 40mm in Visit 1 and Visit 2;

 Exclusion Criteria:

 -  Creatinine clearance < 60 mL/min;

 -  Platelet count < 100 × 103/mm3 ; White blood cell (WBC) count < 2500 / mm3; Neutrophil
 count < 1500/ mm3;

 -  Subjects who are expected to require surgery during the trial;